[HTML][HTML] Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer
Y Bai, L Zhou, C Zhang, M Guo, L Xia, Z Tang, Y Liu… - Oncogene, 2023 - nature.com
The drug therapy for non-small cell lung cancer (NSCLC) have always been issues of
poisonous side effect, acquired drug resistance and narrow applicable population. In this …
poisonous side effect, acquired drug resistance and narrow applicable population. In this …
Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer.
Y Bai, L Zhou, C Zhang, M Guo, L Xia, Z Tang, Y Liu… - Oncogene, 2023 - europepmc.org
The drug therapy for non-small cell lung cancer (NSCLC) have always been issues of
poisonous side effect, acquired drug resistance and narrow applicable population. In this …
poisonous side effect, acquired drug resistance and narrow applicable population. In this …
Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer
Y Bai, L Zhou, C Zhang, M Guo, L Xia, Z Tang… - …, 2023 - pubmed.ncbi.nlm.nih.gov
The drug therapy for non-small cell lung cancer (NSCLC) have always been issues of
poisonous side effect, acquired drug resistance and narrow applicable population. In this …
poisonous side effect, acquired drug resistance and narrow applicable population. In this …
[HTML][HTML] Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer
Y Bai, L Zhou, C Zhang, M Guo, L Xia, Z Tang, Y Liu… - Oncogene, 2023 - ncbi.nlm.nih.gov
The drug therapy for non-small cell lung cancer (NSCLC) have always been issues of
poisonous side effect, acquired drug resistance and narrow applicable population. In this …
poisonous side effect, acquired drug resistance and narrow applicable population. In this …
Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer.
Y Bai, L Zhou, C Zhang, M Guo, L Xia, Z Tang, Y Liu… - Oncogene, 2023 - europepmc.org
The drug therapy for non-small cell lung cancer (NSCLC) have always been issues of
poisonous side effect, acquired drug resistance and narrow applicable population. In this …
poisonous side effect, acquired drug resistance and narrow applicable population. In this …